We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-10.66%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$551M
AUM Growth
–
Cap. Flow
+$550M
Cap. Flow %
99.74%
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$21.7M
2
GILD icon
Gilead Sciences
GILD
+$21M
3
MDT icon
Medtronic
MDT
+$20.8M
4
BIIB icon
Biogen
BIIB
+$20.2M
5
AMGN icon
Amgen
AMGN
+$15.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 93%
2 Financials 1.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
26
Incyte
INCY
$23.4B
$6.59M 1.2%
+91,000
New +$6.78M
CI icon
27
Cigna
CI
$74.5B
$6.59M 1.2%
+48,000
New +$6.59M
CNC icon
28
Centene
CNC
$32.8B
$6.52M 1.18%
+211,760
New +$6.32M
EW icon
29
Edwards Lifesciences
EW
$49.4B
$6.44M 1.17%
+219,000
New +$6.04M
CHRS icon
30
Coherus Oncology
CHRS
$216M
$6.09M 1.11%
+287,000
New +$4.7M
SHPG
31
DELISTED
Shire pic
SHPG
$5.82M 1.06%
+33,880
New +$5.67M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.99B
$5.59M 1.01%
+138,000
New +$5.61M
HUM icon
33
Humana
HUM
$48B
$5.49M 1%
+30,000
New +$5.2M
JNJ icon
34
Johnson & Johnson
JNJ
$609B
$5.41M 0.98%
+50,000
New +$5.18M
MNK
35
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$5.39M 0.98%
+88,000
New +$5.63M
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.36M 0.97%
+65,000
New +$5.29M
BAX icon
37
Baxter International
BAX
$11.7B
$5.34M 0.97%
+130,000
New +$4.95M
VRTX icon
38
Vertex Pharmaceuticals
VRTX
$123B
$5.25M 0.95%
+66,000
New +$5.97M
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.14M 0.93%
+310,000
New +$5.42M
BCR
40
DELISTED
CR Bard Inc.
BCR
$5.07M 0.92%
+25,000
New +$4.72M
AET
41
DELISTED
Aetna Inc
AET
$5.06M 0.92%
+45,000
New +$4.82M
ENDP
42
DELISTED
Endo International plc
ENDP
$4.81M 0.87%
+171,000
New +$8.08M
HCA icon
43
HCA Healthcare
HCA
$82.3B
$4.68M 0.85%
+60,000
New +$4.19M
INSY
44
DELISTED
Insys Therapeutics, Inc.
INSY
$4.49M 0.82%
+281,000
New +$5.34M
PRGO icon
45
Perrigo
PRGO
$1.48B
$4.17M 0.76%
+32,600
New +$4.46M
ELV icon
46
Elevance Health
ELV
$80.9B
$4.17M 0.76%
+30,000
New +$4.01M
ESRX
47
DELISTED
Express Scripts Holding Company
ESRX
$4.03M 0.73%
+58,600
New +$4.21M
XENT
48
DELISTED
Intersect ENT, Inc
XENT
$3.98M 0.72%
+209,246
New +$3.79M
BMY icon
49
Bristol-Myers Squibb
BMY
$124B
$3.83M 0.7%
+60,000
New +$3.78M
EGBN icon
50
Eagle Bancorp
EGBN
$835M
$3.78M 0.69%
+93,400
New +$4.39M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2016 Portfolio in Review

Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.

Its largest position is Celgene Corp: 210,550 shares worth $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Financials.

  • Bellevue Group's largest Q1 2016 buy was Celgene Corp: 210,550 shares worth $21.1M.
  • Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
  • Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.

Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.